VeriMomDois-je éviter naproxen pendant la grossesse ? | VeriMom
Systemic naproxen (an NSAID) is associated with fetal risks including oligohydramnios and premature closure of the ductus arteriosus; regulatory reviews and clinical guidance advise avoiding NSAIDs in pregnancy (especially after 20 weeks). Mechanistically this is via COX inhibition / reduced prostaglandins with demonstrated placental transfer. For topical cosmetic use, systemic exposure is expected to be low (low but measurable), so hazard is 'suspected' rather than confirmed. Sources: FDA/clinical review, peer‑reviewed reviews on NSAIDs in pregnancy, ECHA registration data.
ECHA regulatory hazard statements
- •H361
What to use instead
Pregnancy-safe ingredients that serve a similar function:
FAQ
- naproxen est-il sûr pendant la grossesse ?
- Systemic naproxen (an NSAID) is associated with fetal risks including oligohydramnios and premature closure of the ductus arteriosus; regulatory reviews and clinical guidance advise avoiding NSAIDs in pregnancy (especially after 20 weeks). Mechanistically this is via COX inhibition / reduced prostaglandins with demonstrated placental transfer. For topical cosmetic use, systemic exposure is expected to be low (low but measurable), so hazard is 'suspected' rather than confirmed. Sources: FDA/clinical review, peer‑reviewed reviews on NSAIDs in pregnancy, ECHA registration data.
- naproxen est-il sûr pendant l'allaitement ?
- Naproxen is excreted into breast milk in low amounts but has a long half‑life and case reports of infant effects; professional guidance (LactMed, NHS Specialist Pharmacy Service, MotherToBaby) recommends caution and short‑term use if needed and consideration of alternative NSAIDs with shorter half‑lives. Mechanism is passive transfer into milk consistent with systemic exposure; expected exposure from topical cosmetic use is low but measurable.
- naproxen est-il sûr pour la peau de bébé ?
- No infant‑specific dermal teratogenicity data were found; systemic hazard stems from naproxen’s known reproductive effects. For baby (0–3 yr) skin, exposure scoring is increased by +1 due to immature barrier and higher surface‑area‑to‑weight, so exposure is moderate if a naproxen‑containing topical product were used repeatedly. There is no evidence to raise hazard or mechanism above the adult systemic evidence without infant‑specific studies.
- Comment VeriMom évalue-t-il naproxen ?
- VeriMom évalue naproxen à 20/100 (risque élevé) sur la base du statut EU CosIng, des classifications ECHA et des études PubMed.
- Quelles sont les alternatives sûres à naproxen pendant la grossesse ?
- Consultez notre liste d'alternatives sûres à naproxen basée sur une fonction similaire et une classification sans risques connus.
Vérifiez chaque étiquette en 2 secondes
Obtenez VeriMom gratuitement — scannez n'importe quel produit et voyez le score de sécurité grossesse instantanément.
Avis Médical
Ces informations sont fournies à titre éducatif uniquement et ne constituent pas un avis médical. Les scores de sécurité sont basés sur des données accessibles au public et peuvent ne pas refléter tous les risques. Consultez toujours votre professionnel de santé avant d'utiliser tout produit pendant la grossesse ou l'allaitement.